<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:admin="http://webns.net/mvcb/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:content="http://purl.org/rss/1.0/modules/content/">

    <channel>
    
    <title>Amgen News Service
</title>
    <link>http://www.amgennews.com/index.php</link>
    <description></description>
    <dc:language>en</dc:language>
    <dc:creator>piroc@piroc.com</dc:creator>
    <dc:rights>Copyright 2008</dc:rights>
    <dc:date>2008-06-18T15:06:00+00:00</dc:date>
    <admin:generatorAgent rdf:resource="http://expressionengine.com/" />
    

    <item>
      <title>Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_and_wyeth_statement_on_outcome_of_dermatologic_and_ophthalmic_drugs_a/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_and_wyeth_statement_on_outcome_of_dermatologic_and_ophthalmic_drugs_a/#When:15:06:00Z</guid>
      <description>&amp;nbsp;FDA Advisory Committee Recommends Enbrel(R) (etanercept) for the Treatment of Children and Adolescents with Chronic Moderate to Severe Plaque Psoriasis
THOUSAND OAKS, Calif. &amp;amp; COLLEGEVILLE, Pa. &amp;ndash; June 18, 2008 &amp;ndash; Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today issued the following statement on the outcome of today&#8217;s meeting of the U.S. Food and Drug Administration&#8217;s (FDA) Dermatologic and Ophthalmologic Drug Advisory Committee (DODAC) regarding the expanded use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis.</description>
      <dc:subject>Press Releases, Product News</dc:subject>
      <dc:date>2008-06-18T15:06:00+00:00</dc:date>
    </item>

    <item>
      <title>Enbrel(R) (etanercept) Application for the Treatment of Pediatric Psoriasis to be Discussed at FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/enbrel_application_for_the_treatment_of_pediatric_psoriasis_to_be_discussed/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/enbrel_application_for_the_treatment_of_pediatric_psoriasis_to_be_discussed/#When:05:15:00Z</guid>
      <description>&amp;nbsp;ENBREL Reviewed As Potential New Treatment Option for Children and Adolescents with Chronic Moderate to Severe Plaque Psoriasis Who Have Tried Another Therapy
THOUSAND OAKS, Calif.&#45;&#45;(BUSINESS WIRE)&#45;&#45;June 18, 2008&#45;&#45;Amgen (NASDAQ:AMGN) announced that the supplemental Biologics License Application (sBLA) for ENBREL for the treatment of pediatric patients with chronic moderate to severe plaque psoriasis who have tried another therapy will be discussed today at a meeting of the DODAC. Moderate to severe plaque psoriasis is a serious, chronic inflammatory disease that can have both physical and psychosocial impact. According to a study published in the British Journal of Dermatology, chronic psoriasis can have as much of an impact on a child&#8217;s physical, psychological and social functioning as other serious childhood diseases such as asthma, epilepsy and diabetes.</description>
      <dc:subject>Press Releases, Product News</dc:subject>
      <dc:date>2008-06-18T05:15:00+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Statement on Briefing Materials Prepared for June 18, 2008 DODAC Meeting</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_statement_on_briefing_materials_prepared_for_june_18_2008_dodac_meeti/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_statement_on_briefing_materials_prepared_for_june_18_2008_dodac_meeti/#When:06:14:01Z</guid>
      <description>Briefing documents for the June 18 Dermatologic and Ophthalmic Drugs Advisory (DODAC) meeting regarding the supplemental biologics license application (sBLA) for Enbrel&amp;reg; (etanercept) for the treatment of moderate to severe plaque psoriasis in the pediatric population are now available at www.fda.gov.
Amgen believes that ENBREL would provide an important clinical option if approved for this small, under&#45;served population of children with moderate to severe plaque psoriasis, and looks forward to discussing with the DODAC and FDA the benefits and risks of ENBREL treatment for these patients who have few approved therapies to help manage their disease.</description>
      <dc:subject>Product News</dc:subject>
      <dc:date>2008-06-16T06:14:01+00:00</dc:date>
    </item>

    <item>
      <title>Romiplostim Data Show Potential Long&#45;Term Efficacy and Safety in Adults with Chronic ITP</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/romiplostim_data_show_potential_long_term_efficacy_and_safety_in_adults_wit/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/romiplostim_data_show_potential_long_term_efficacy_and_safety_in_adults_wit/#When:05:45:00Z</guid>
      <description>COPENHAGEN, Denmark &amp;ndash; June 15, 2008 &amp;ndash; Amgen Inc. (NASDAQ: AMGN) today announced updated results from the ongoing, open&#45;label extension study on the long&#45;term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The updated results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue ITP medications.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-06-15T05:45:00+00:00</dc:date>
    </item>

    <item>
      <title>Amgen SVP of North American Commercial Operations James Daly to Present at the Goldman Sachs Healthcare Conference</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_svp_james_daly_to_present_at_the_goldman_sachs_healthcare_conference/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_svp_james_daly_to_present_at_the_goldman_sachs_healthcare_conference/#When:11:41:01Z</guid>
      <description>THOUSAND OAKS, Calif. &amp;ndash; June 9, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) Senior Vice President of North American Commercial Operations James Daly will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11, 2008 beginning at 8:40 a.m. Pacific Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen&#8217;s Web site, http://www.amgen.com, under Investors.</description>
      <dc:subject>Press Releases</dc:subject>
      <dc:date>2008-06-09T11:41:01+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Names Anna Richo Senior Vice President of Worldwide Compliance</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/anna_richo_senior_vice_president_of_worldwide_compliance/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/anna_richo_senior_vice_president_of_worldwide_compliance/#When:08:27:00Z</guid>
      <description>THOUSAND OAKS, Calif. &amp;ndash; Jun 06, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced the appointment of Anna S. Richo as senior vice president, Worldwide Compliance. Richo will head the organization responsible for Amgen&#8217;s corporate compliance and business ethics programs. She will report to Amgen Chairman and Chief Executive Officer Kevin Sharer.</description>
      <dc:subject>Press Releases</dc:subject>
      <dc:date>2008-06-06T08:27:00+00:00</dc:date>
    </item>

    <item>
      <title>Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_and_wyeth_statement_on_the_fda_early_communication_about_tumor_necros/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_and_wyeth_statement_on_the_fda_early_communication_about_tumor_necros/#When:06:58:00Z</guid>
      <description>THOUSAND OAKS, Calif. &amp;amp; COLLEGEVILLE, Pa. &amp;ndash; Jun 04, 2008 &amp;ndash; Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) Early Communication regarding an ongoing safety review of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade, Enbrel, Humira and Cimzia) and the possible association between the use of these medicines and the development of lymphoma and other cancers in children and young adults. These individuals were treated with TNF blockers for Juvenile Idiopathic Arthritis (JIA), Crohn&#8217;s disease or other diseases.</description>
      <dc:subject>Press Releases</dc:subject>
      <dc:date>2008-06-04T06:58:00+00:00</dc:date>
    </item>

    <item>
      <title>Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/updated_data_from_ongoing_phase_3_trials/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/updated_data_from_ongoing_phase_3_trials/#When:06:44:01Z</guid>
      <description>CHICAGO &amp;ndash; June 1, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced updated interim pooled, blinded, safety results from two Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with standard chemotherapy in earlier lines of metastatic colorectal cancer (mCRC). Updated data from these trials, as well as the first prospective trial evaluating the impact of the clinical biomarker KRAS on Vectibix efficacy in combination with chemotherapy, were presented at the 2008 American Society of Clinical Oncology&#8217;s (ASCO) Annual Meeting in Chicago.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-06-01T06:44:01+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_presents_new_data_at_asco_on_four_investigational_molecules_from_onco/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_presents_new_data_at_asco_on_four_investigational_molecules_from_onco/#When:17:15:01Z</guid>
      <description>CHICAGO &amp;ndash; May 31, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced interim results from four of the company&#8217;s investigational cancer agents. Data presented from trials with recombinant human (rh) Apo2L/TRAIL, AMG 479, AMG 102 and motesanib alone, and in combination with chemotherapy or other targeted agents, are a part of the robust oncology therapeutic development program organized in the pathway areas of apoptosis, growth regulation and angiogenesis. These studies were presented at the 2008 American Society of Clinical Oncology&#8217;s (ASCO) Annual Meeting in Chicago.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-31T17:15:01+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_reports_positive_data_at_asco_from_three_studies_of_denosumab_in_canc/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_reports_positive_data_at_asco_from_three_studies_of_denosumab_in_canc/#When:17:04:00Z</guid>
      <description>CHICAGO &amp;ndash; May 31, 2008 &amp;ndash; Amgen (NASDAQ: AMGN) today announced results from three denosumab studies in cancer patients. A Phase 2 study of metastatic patients previously treated with IV bisphosphonates found that denosumab normalized a key marker of bone resorption at a significantly greater rate than that seen with continuation of IV bisphosphonates, and also patients receiving denosumab experienced fewer skeletal&#45;related events (SREs). A separate retrospective analysis comparing the results of this study to another Phase 2 study of patients never treated with an IV bisphosphonate revealed that the effect of denosumab on bone turnover markers was similar regardless of previous exposure to bisphosphonates. In addition, a sub&#45;analysis of a Phase 3 trial in an earlier&#45;stage cancer population of non&#45;metastatic breast cancer patients showed that denosumab increased bone mineral density (BMD) at all sites measured, including cortical bone. These results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-31T17:04:00+00:00</dc:date>
    </item>

    
    </channel>
</rss>